Bristol Myers Secures FDA Nod For Opdivo Plus Chemo For Untreated Hodgkin Lymphoma

NodeGuardian · 2026-03-25T00:13:33+00:00

Bristol Myers Squibb's Opdivo (nivolumab) has gained FDA approval for treating untreated Stage III or IV classical Hodgkin lymphoma in patients aged 12 and older, based on positive study results. The treatment generated significant revenue in 2025 despite a slight dip in shares.

NodeGuardian

2026-03-25 00:13:33

Abstract generation in progress

Bristol Myers Squibb (NYSE: BMY) has received FDA approval for Opdivo (nivolumab) combined with chemotherapy for adult and pediatric patients aged 12 and older with previously untreated Stage III or IV classical Hodgkin lymphoma. The approval is based on Study CA209-8UT which showed superior progression-free survival for nivolumab plus AVD. Opdivo generated $5.9 billion in revenues in 2025, and the company’s shares were down 1.33% at $57.34 at the time of publication.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.